Claims for Patent: 9,364,567

Summary for Patent: 9,364,567

Title:	Fragments of p97 and uses thereof
Abstract:	Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising the p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB.
Inventor(s):	Vitalis; Timothy Z. (Vancouver, CA), Gabathuler; Reinhard (Montreal, CA)
Assignee:	biOasis Technologies, Inc. (Richmond, CA)
Application Number:	14/210,029
Patent Claims:	1. A composition, comprising a conjugate and a pharmaceutically acceptable carrier, where the conjugate comprises at least one isolated p97 polypeptide of up to 50 amino acids in length, where the polypeptide comprises an amino acid sequence at least 80% identical to DSSHAFTLDELR (SEQ ID NO:13), and where the p97 polypeptide is covalently or operatively linked to an agent, to form a p97-agent conjugate. 2. The composition of claim 1, where the p97 polypeptide comprises DSSHAFTLDELR (SEQ ID NO:13). 3. The composition of claim 1, where the p97 polypeptide comprises 2, 3, or 4 of DSSHAFTLDELR (SEQ ID NO:13). 4. The composition of claim 1, where the p97 polypeptide consists of SEQ ID NO:13, and optionally a C-terminal cysteine, a C-terminal tyrosine, or both. 5. The composition of claim 1, where the p97 polypeptide is up to 20 amino acids in length. 6. The composition of claim 1, where the conjugate is a fusion protein. 7. The composition of claim 1, where the agent is a molecule having a molecular weight of 50 to 2000 daltons, a polypeptide, a peptide mimetic, a peptoid, or an aptamer. 8. The composition of claim 7, where the molecule is a cytotoxic or chemotherapeutic or anti-angiogenic agent selected from one or more of alkylating agents, anti-metabolites, anthracyclines, anti-tumor antibiotics, platinums, type I topoisomerase inhibitors, type II topoisomerase inhibitors, vinca alkaloids, and taxanes. 9. The composition of claim 7, where the molecule is selected from one or more of chlorambucil, cyclophosphamide, cilengitide, lomustine (CCNU), melphalan, procarbazine, thiotepa, carmustine (BCNU), enzastaurin, busulfan, daunorubicin, doxorubicin, gefitinib, erlotinib idarubicin, temozolomide, epirubicin, mitoxantrone, bleomycin, cisplatin, carboplatin, oxaliplatin, camptothecins, irinotecan, topotecan, amsacrine, etoposide, etoposide phosphate, teniposide, temsirolimus, everolimus, vincristine, vinblastine, vinorelbine, vindesine, CT52923, paclitaxel, imatinib, dasatinib, sorafenib, pazopanib, sunitnib, vatalanib, geftinib, erlotinib, AEE-788, dichoroacetate, tamoxifen, fasudil, SB-681323, semaxanib, donepizil, galantamine, memantine, rivastigmine, tacrine, rasigiline, naltrexone, lubiprostone, safinamide, istradefylline, pimavanserin, pitolisant, isradipine, pridopidine (ACR16), tetrabenazine, bexarotene, glatirimer acetate, fingolimod, and mitoxantrone, including pharmaceutically acceptable salts and acids thereof. 10. The composition of claim 7, where the polypeptide is an antibody or antigen-binding fragment thereof. 11. The composition of claim 10, where the antibody or antigen-binding fragment thereof specifically binds to a cancer-associated antigen. 12. The composition of claim 11, where the cancer-associated antigen is one or more of human Her2/neu, Her1/EGF receptor (EGFR), Her3, A33 antigen, B7H3, CD5, CD19, CD20, CD22, CD23 (IgE Receptor), C242 antigen, 5T4, IL-6, IL-13, vascular endothelial growth factor VEGF (e.g., VEGF-A) VEGFR-1, VEGFR-2, CD30, CD33, CD37, CD40, CD44, CD51, CD52, CD56, CD74, CD80, CD152, CD200, CD221, CCR4, HLA-DR, CTLA-4, NPC-1C, tenascin, vimentin, insulin-like growth factor 1 receptor (IGF-1R), alpha-fetoprotein, insulin-like growth factor 1 (IGF-1), carbonic anhydrase 9 (CA-IX), carcinoembryonic antigen (CEA), integrin .alpha.v.beta.3, integrin .alpha.5.beta.1, folate receptor 1, transmembrane glycoprotein NMB, fibroblast activation protein alpha (FAP), glycoprotein 75, TAG-72, MUC1, MUC16 (or CA-125), phosphatidylserine, prostate-specific membrane antigen (PMSA), NR-LU-13 antigen, TRAIL-R1, tumor necrosis factor receptor superfamily member 10b (TNFRSF10B or TRAIL-R2), SLAM family member 7 (SLAMF7), EGP40 pancarcinoma antigen, B-cell activating factor (BAFF), platelet-derived growth factor receptor, glycoprotein EpCAM (17-1A), Programmed Death-1, protein disulfide isomerase (PDI), Phosphatase of Regenerating Liver 3 (PRL-3), prostatic acid phosphatase, Lewis-Y antigen, GD2 (a disialoganglioside expressed on tumors of neuroectodermal origin), glypican-3 (GPC3), or mesothelin. 13. The composition of claim 10, where the antibody or antigen-binding fragment thereof specifically binds to a pain-associated antigen. 14. The composition of claim 13, where the pain associated-antigen is one or more of nerve growth factor (NGF) or tropomyosin-related kinase A (TrkA). 15. The composition of claim 10, where the antibody or antigen-binding fragment thereof specifically binds to a pro-inflammatory molecule, optionally a pro-inflammatory cytokine or chemokine. 16. The composition of claim 15, where the pro-inflammatory molecule is one or more of TNF-.alpha., TNF-.beta., FasL, CD27L, CD30L, CD40L, Ox40L, 4-1BBL, TRAIL, TWEAK, and Apo3L, IL-1.alpha., IL-1.beta., IL-2, interferon-.gamma. (IFN-.gamma.), IFN-.alpha., IFN-.beta., IL-6, IL-8, IL-12, IL-15, IL-17, IL-18, IL-21, LIF, CCL5, GRO.alpha., MCP-1, MIP-1.alpha., MIP-1.beta., macrophage colony stimulating factor (MCSF), or granulocyte macrophage colony stimulating factor (GM-CSF). 17. The composition of claim 16, where the pro-inflammatory molecule is TNF-.alpha., and where the antibody or antigen-binding fragment is adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, D2E7, CDP 571, or CDP 870, or an antigen-binding fragment or variant thereof. 18. The composition of claim 10, wherein the antibody or antigen-binding fragment thereof specifically binds to one or more of human Her2/neu, Her1/EGFR, TNF-.alpha., B7H3 antigen, CD20, VEGF, CD52, CD33, CTLA-4, tenascin, alpha-4 (.alpha.4) integrin, IL-23, amyloid-.beta., Huntingtin, CD25, nerve growth factor (NGF), TrkA, or .alpha.-synuclein. 19. The composition of claim 10, where the antibody is selected from one or more of trastuzumab, cetuximab, daclizumab, tanezumab, 3F8, 8H9, abagovomab, adecatumumab, afutuzumab, alemtuzumab, alacizumab (pegol), amatuximab, apolizumab, bavituximab, bectumomab, belimumab, bevacizumab, bivatuzumab (mertansine), brentuximab vedotin, cantuzumab (mertansine), cantuzumab (ravtansine), capromab (pendetide), catumaxomab, citatuzumab (bogatox), cixutumumab, clivatuzumab (tetraxetan), conatumumab, dacetuzumab, dalotuzumab, detumomab, drozitumab, ecromeximab, edrecolomab, elotuzumab, enavatuzumab, ensituximab, epratuzumab, ertumaxomab, etaracizumab, farletuzumab, FBTA05, figitumumab, flanvotumab, galiximab, gemtuzumab, ganitumab, gemtuzumab (ozogamicin), girentuximab, glembatumumab (vedotin), ibritumomab tiuxetan, icrucumab, igovomab, indatuximab ravtansine, intetumumab, inotuzumab ozogamicin, ipilimumab (MDX-101), iratumumab, labetuzumab, lexatumumab, lintuzumab, lorvotuzumab (mertansine), lucatumumab, lumiliximab, mapatumumab, matuzumab, milatuzumab, mitumomab, mogamulizumab, moxetumomab (pasudotox), nacolomab (tafenatox), naptumomab (estafenatox), narnatumab, necitumumab, nimotuzumab, nivolumab, Neuradiab.RTM. (with or without radioactive iodine), NR-LU-10, ofatumumab, olaratumab, onartuzumab, oportuzumab (monatox), oregovomab, panitumumab, patritumab, pemtumomab, pertuzumab, pritumumab, racotumomab, radretumab, ramucirumab, rilotumumab, rituximab, robatumumab, samalizumab, sibrotuzumab, siltuximab, tabalumab, taplitumomab (paptox), tenatumomab, teprotumumab, TGN1412, ticilimumab, tremelimumab, tigatuzumab, TNX-650, tositumomab, TRBS07, tucotuzumab (celmoleukin), ublituximab, urelumab, veltuzumab, volociximab, votumumab, and zalutumumab, including antigen-binding fragments thereof. 20. The composition of claim 7, where the polypeptide is an interferon-.beta. polypeptide, or an active fragment or variant thereof. 21. The composition of claim 7, where the polypeptide associates with a lysosomal storage disease. 22. The composition of claim 21, where the polypeptide is selected from one or more of aspartylglucosaminidase, acid lipase, cysteine transporter, Lamp-2, .alpha.-galactosidase A, acid ceramidase, .alpha.-L-fucosidase, .beta.-hexosaminidase A, GM2-ganglioside activator (GM2A), .alpha.-D-mannosidase, .beta.-D-mannosidase, arylsulfatase A, saposin B, neuraminidase, .alpha.-N-acetylglucosaminidase phosphotransferase, phosphotransferase .gamma.-subunit, L-iduronidase, iduronate-2-sulfatase, heparan-N-sulfatase, .alpha.-N-acetylglucosaminidase, acetylCoA:N-acetyltransferase, N-acetylglucosamine 6-sulfatase, galactose 6-sulfatase, .beta.-galactosidase, N-acetylgalactosamine 4-sulfatase, hyaluronoglucosaminidase, sulfatases, palmitoyl protein thioesterase, tripeptidyl peptidase I, acid sphingomyelinase, cathepsin A, cathepsin K, .alpha.-galactosidase B, NPC1, NPC2, sialin, and sialic acid transporter, including active fragments and variants thereof. 23. The composition of claim 7, where the agent is a cardiotoxic agent in its unconjugated form. 24. The composition of claim 23, where the cardiotoxic agent is an anthracycline/anthraquinolone, cyclophosphamide, antimetabolite, antimicrotubule agent, tyrosine kinase inhibitor, bevacizumab, or trastuzumab. 25. The composition of claim 23, where the cardiotoxic agent is cyclopentenyl cytosine, 5-fluorouracil, capecitabine, paclitaxel, docataxel, adriamycin, doxorubucin, epirubicin, emetine, isotamide, mitomycin C, erlotinib, gefitinib, imatinib, sorafenib, sunitinib, cisplatin, thalidomide, busulfan, vinblastine, bleomycin, vincristine, arsenic trioxide, methotrexate, rosiglitazone, or mitoxantrone.

Details for Patent 9,364,567

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Aytu Bioscience, Inc.	PROSTASCINT	capromab pendetide	Injection	103608	10/28/1996		2033-03-13
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2033-03-13
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2033-03-13
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	12/10/1997		2033-03-13
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2033-03-13
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2033-03-13